Clinical utility of tumor-infiltrating lymphocyte evaluation by two different methods in breast cancer patients treated with neoadjuvant chemotherapy.

The high/intermediate-TIL group showed a trend toward better DFS ( p = 0.14, Fig. 3 b) and significantly better OS ( p = 0.03, Fig. 3 d) than the low-TIL group by the average method, although analysis using the hot-spot data did not show any significant difference either in DFS or OS (Fig. 3 a, c).

also in 53,322 other papers